The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice

Dannielle D. Engle, Hervé Tiriac, Keith D. Rivera, Arnaud Pommier, Sean Whalen, Tobiloba E. Oni, Brinda Alagesan, Eun Jung Lee, Melissa A. Yao, Matthew S. Lucito, Benjamin Spielman, Brandon Da Silva, Christina Schoepfer, Kevin Wright, Brianna Creighton, Lauren Afinowicz, Kenneth H. Yu, Robert Grützmann, Daniela Aust, Phyllis A. GimottyKatherine S. Pollard, Ralph H. Hruban, Michael G. Goggins, Christian Pilarsky, Youngkyu Park, Darryl J. Pappin, Michael A. Hollingsworth, David A. Tuveson

Research output: Contribution to journalArticlepeer-review

165 Scopus citations


Glycosylation alterations are indicative of tissue inflammation and neoplasia, but whether these alterations contribute to disease pathogenesis is largely unknown. To study the role of glycan changes in pancreatic disease, we inducibly expressed human fucosyltransferase 3 and b1,3-galactosyltransferase 5 in mice, reconstituting the glycan sialyl-Lewisa, also known as carbohydrate antigen 19-9 (CA19-9). Notably, CA19-9 expression in mice resulted in rapid and severe pancreatitis with hyperactivation of epidermal growth factor receptor (EGFR) signaling. Mechanistically, CA19-9 modification of the matricellular protein fibulin-3 increased its interaction with EGFR, and blockade of fibulin-3, EGFR ligands, or CA19-9 prevented EGFR hyperactivation in organoids. CA19-9–mediated pancreatitis was reversible and could be suppressed with CA19-9 antibodies. CA19-9 also cooperated with the KrasG12D oncogene to produce aggressive pancreatic cancer. These findings implicate CA19-9 in the etiology of pancreatitis and pancreatic cancer and nominate CA19-9 as a therapeutic target.

Original languageEnglish (US)
Pages (from-to)1156-1162
Number of pages7
Issue number6446
StatePublished - 2019

ASJC Scopus subject areas

  • General


Dive into the research topics of 'The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice'. Together they form a unique fingerprint.

Cite this